Page 79 - GALENIKA MEDICAL JOURNAL

Literatura 15. Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR,
Patel MR, et al. Rivaroxaban in Peripheral Artery Disease after
Revascularization. N Engl J Med. 2020 May 21;382(21):1994-2004.
1. Abu Dabrh AM, Steffen MW, Undavalli C, Asi N, Wang Z, Elamin
MB, et al. The natural history of untreated severe or critical 16. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV,
limb ischemia. J Vasc Surg. 2015 Dec;62(6):1642-51.e3. Kakkar AK, et al; RECORD1 Study Group. Rivaroxaban
versus enoxaparin for thromboprophylaxis after hip
2. Song P, Rudan D, Zhu FJY, Fowkes F, Rahimi K, Fowkes FGR, et arthroplasty. N Engl J Med. 2008 Jun 26;358(26):2765-75.
al. Global, regional, and national prevalence and risk factors for
peripheral artery disease in 2015: an updated systematic review 17. Samama CM, Laporte S, Rosencher N, Girard P, Llau J, Mouret P, et al;
and analysis. Lancet Glob Health. 2019 Aug;7(8):e1020-30. PRONOMOS Investigators. Rivaroxaban or Enoxaparin in Nonmajor
Orthopedic Surgery. N Engl J Med. 2020 May 14;382(20):1916-25.
3. Bonaca MP, Gutierrez JA, Creager MA, Scirica BM, Olin J, Murphy SA,
et al. Acute Limb Ischemia and Outcomes With Vorapaxar in Patients 18. Spronk HM, de Jong AM, Crijns HJ, Schotten U, Van Gelder IC, Ten Cate
With Peripheral Artery Disease: Results From the Trial to Assess H. Pleiotropic effects of factor Xa and thrombin: what to expect from
the Effects of Vorapaxar in Preventing Heart Attack and Stroke in novel anticoagulants. Cardiovasc Res. 2014 Mar 1;101(3):344-51.
Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 19. Borensztajn K, Spek CA. Blood coagulation factor Xa as an emerging
50 (TRA2°P-TIMI 50). Circulation. 2016 Mar 8;133(10):997-1005. drug target. Expert Opin Ther Targets. 2011 Mar;15(3):341-9.
4. Anderson K, Odell P, Wilson P, Kannel W. Cardiovascular disease 20. Tantry U, Cummings C, Mackrell P, Gonze M, Ulloa K, Bafford R, et al.
risk profiles. Am Heart J. 1991 Jan;121(1 Pt 2):293-8. Synergistic influence of rivaroxaban on inflammation and coagulation
5. Narula N, Dannenberg AJ, Olin JW, Bhatt DL, Johnson KW, Nadkarni G, biomarkers in patients with coronary artery disease and peripheral
et al. Pathology of Peripheral Artery Disease in Patients With Critical artery disease on aspirin therapy. Future Cardiol. 2020 Mar;16(2):69-75.
Limb Ischemia. J Am Coll Cardiol. 2018 Oct 30;72(18):2152-63. 21. Kaplovitch E, Eikelboom JW, Dyal L, Aboyans V, Abola MT, Verhamme
6. Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge P, et al. Rivaroxaban and Aspirin in Patients With Symptomatic Lower
R, et al; GVG Writing Group. Global vascular guidelines Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS
on the management of chronic limb-threatening Randomized Clinical Trial. JAMA Cardiol. 2021 Jan 1;6(1):21-9.
ischemia. J Vasc Surg. 2019 Jun;69(6S):3S-125S.e40. 22. Moll F, Baumgartner I, Jaff M, Nwachuku C, Tangelder M, Ansel G, et al;
7. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel ePAD Investigators. Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy
versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE in Endovascular Treatment of Patients With Peripheral Artery Disease:
Steering Committee. Lancet. 1996 Nov 16;348(9038):1329-39. Results of the ePAD Trial. J Endovasc Ther. 2018 Apr;25(2):158-68.
8. Hiatt WR, Fowkes FG, Heizer G, Berger JS, Baumgartner I, Held 23. Biagioni RB, Lopes RD, Agati LB, Sacilotto R, Wolosker N, Sobreira ML, et
P, et al; EUCLID Trial Steering Committee and Investigators. al. Rationale and design for the study Apixaban versus ClopidoGRel on a
Ticagrelor versus Clopidogrel in Symptomatic Peripheral background of aspirin in patient undergoing InfraPoPliteal angioplasty
Artery Disease. N Engl J Med. 2017 Jan 5;376(1):32-40. for critical limb ischemia: AGRIPPA trial. Am Heart J. 2020 Sep;227:100-6.
9. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish 24. Lapébie FX, Aboyans V, Lacroix P, Constans J, Boulon C, Messas
MP, et al; TRA 2P–TIMI 50 Steering Committee and Investigators. E, et al. Editor's Choice - External Applicability of the COMPASS
Vorapaxar in the secondary prevention of atherothrombotic and VOYAGER-PAD Trials on Patients with Symptomatic Lower
events. N Engl J Med. 2012 Apr 12;366(15):1404-13. Extremity Artery Disease in France: The COPART Registry.
Eur J Vasc Endovasc Surg. 2021 Sep;62(3):439-49.
10. Bedenis R, Lethaby A, Maxwell H, Acosta S, Prins MH. Antiplatelet
agents for preventing thrombosis after peripheral arterial bypass 25. Fox KAA, Anand SS, Aboyans V, Cowie MR, Debus ES, Zeymer
surgery. Cochrane Database Syst Rev. 2015 Feb 19;2015(2):CD000535. U, et al. Xarelto plus Acetylsalicylic acid: Treatment patterns
and Outcomes in patients with Atherosclerosis (XATOA):
11. Strobl FF, Brechtel K, Schmehl J, Zeller T, Reiser MF, Claussen CD, et Rationale and design of a prospective registry study to assess
al. Twelve-month results of a randomized trial comparing mono with rivaroxaban 2.5 mg twice daily plus aspirin for prevention of
dual antiplatelet therapy in endovascularly treated patients with atherothrombotic events in coronary artery disease, peripheral
peripheral artery disease. J Endovasc Ther. 2013 Oct;20(5):699-706. artery disease, or both. Am Heart J. 2020 Apr;222:166-73.
12. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group.
Efficacy of oral anticoagulants compared with aspirin after infrainguinal
bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin
Study): a randomised trial. Lancet. 2000 Jan 29;355(9201):346-51.
13. Brumberg RS, Back MR, Armstrong PA, Cuthbertson D, Shames Konflikt interesa: Nema
ML, Johnson BL, Bandyk DF. The relative importance of graft
surveillance and warfarin therapy in infrainguinal prosthetic Primljeno: 04. 03. 2022.
bypass failure. J Vasc Surg. 2007 Dec;46(6):1160-6.
Prihvaćeno: 20. 05. 2022.
14. Anand SS, Caron F, Eikelboom JW, Bosch J, Dyal L, Aboyans Onlajn: 30. 06. 2022.
V, et al. Major Adverse Limb Events and Mortality in
Patients With Peripheral Artery Disease: The COMPASS
Trial. J Am Coll Cardiol. 2018 May 22;71(20):2306-15.

REVIJALNI RADOVI Galenika Medical Journal, 2022; 1(2):76-79. 79